Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 132

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 132
---
ured and filled at an Israeli CMO. We intend to add North American and European CMOs when we progress to additional scale-up and
commercial launch needs. We currently have commercial supply agreements with our more strategic suppliers in the United States. and Europe
and continue to seek additional suppliers for strategically essential materials as well.

Some of the critical materials
and components used in manufacturing GelrinC are “off the shelf” components while others are custom-made components for us.
We currently have two suppliers, and to our knowledge, both are GMP compliant.

The following are summary
descriptions of our two supplier agreements to which we are a party.

Baxter Supply Agreement

On July 24, 2008, we entered
into a supply agreement, or the Supply Agreement, with Baxter Healthcare Corporation, or Baxter, and Teva Medical (Marketing) Ltd., or
Teva, which was amended and restated on January 6, 2009, pursuant to which we agreed to purchase Tisseel VHSD fibrin sealant Kit, or Tisseel,
from Teva, with Teva being Baxter’s exclusive distribution agent in Israel for Tisseel, for manufacturing of GelrinC.

<div align='center'>78</div>

The Supply Agreement had an
initial term of 3 years which ended on April 1, 2011 but has an ever-green clause and is automatically renewable for consecutive 1-year
terms (with the exception of pricing, which will be re-negotiated 90 days prior to the expiration of the term), unless either party gives
notice of termination at least 90 days prior to the then current term. The Supply Agreement may be terminated without cause by Baxter
upon 90 days’ prior written notice to the other parties. In addition, either party may terminate the Supply Agreement in the event
of a Voluntary Liquidation Event (as defined in the Supply Agreement), including, but not only, insolvency, and an uncured material breach.

Baxter Services Agreement

On February 27, 2018, we entered
into a services agreement with Baxter, or the Service Agreement, pursuant to which we agreed to purchase certain services from Baxter
in connection with Teva’s supply of Tisseel under the Agreement for manufacturing of GelrinC.

Under the Services Agreement,
Baxter provides us with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for all such
support. In consideration for receiving such support,